Cilengitide fails to meet primary endpoint in patients with newly diagnosed glioblastoma

Merck Serono, a division of Merck, Darmstadt, Germany, has announced that the Phase III CENTRIC trial of the investigational integrin inhibitor cilengitide did not meet its primary endpoint of significantly increasing overall survival when added to the current standard chemoradiotherapy regimen (temozolomide and radiotherapy).
Source: Pharmacy Europe - Category: Drugs & Pharmacology Source Type: news